Company intelligence / Profile preview

Audax Medical

Concord, Massachusetts, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Audax Medical is a privately held medical technology company focused on nanoscale regenerative biomaterials and licensed nanomolecule technology for development of COVID-19 antiviral therapy; available public information indicates programs are at pre-clinical stage with no reported human trial outcomes yet.[2]

Therapeutic areas: RheumatologyOtherInfectious Diseases
Modalities: DeviceHydrogel-based drug delivery therapyBiologic
Industry: Biotech

Drug pipeline

1 asset

Nx3

Preclinical

Partnerships

Northeastern University (license of nanomolecule technology for COVID-19 antiviral therapy)[2]

Beyond the preview

Go deeper on Audax Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Audax Medical.

Explore the full profile